BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30:843-852. [PMID: 14680319 DOI: 10.1016/s0094-0143(03)00056-9] [Cited by in Crossref: 520] [Cited by in F6Publishing: 198] [Article Influence: 28.9] [Reference Citation Analysis]
Number Citing Articles
1 Kumar KA, Sadashivudu G, Krishnamani KV, Linga VG, Maddali LS, Digumarti RR. Managing metastatic renal cell carcinoma-challenges, pitfalls, and outcomes in the real world. Indian J Med Paediatr Oncol 2016;37:260-4. [PMID: 28144093 DOI: 10.4103/0971-5851.195738] [Reference Citation Analysis]
2 Mitsui Y, Shiina H, Kato T, Maekawa S, Hashimoto Y, Shiina M, Imai-Sumida M, Kulkarni P, Dasgupta P, Wong RK, Hiraki M, Arichi N, Fukuhara S, Yamamura S, Majid S, Saini S, Deng G, Dahiya R, Nakajima K, Tanaka Y. Versican Promotes Tumor Progression, Metastasis and Predicts Poor Prognosis in Renal Carcinoma. Mol Cancer Res 2017;15:884-95. [PMID: 28242813 DOI: 10.1158/1541-7786.MCR-16-0444] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 6.6] [Reference Citation Analysis]
3 Chakiryan NH, Jiang DD, Gillis KA, Green E, Hajiran A, Hugar L, Zemp L, Zhang J, Jain RK, Chahoud J, Spiess PE, Sexton W, Gilbert SM, Manley BJ. Real-World Survival Outcomes Associated With First-Line Immunotherapy, Targeted Therapy, and Combination Therapy for Metastatic Clear Cell Renal Cell Carcinoma. JAMA Netw Open 2021;4:e2111329. [PMID: 34032854 DOI: 10.1001/jamanetworkopen.2021.11329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Simonovic S, Hinze C, Schmidt-Ott KM, Busch J, Jung M, Jung K, Rabien A. Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients. BMC Urol 2020;20:7. [PMID: 32013938 DOI: 10.1186/s12894-019-0542-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Louie-Johnsun M, Lalak A. The case for radical nephrectomy. Ann R Coll Surg Engl 2008;90:278-80. [PMID: 18521976 DOI: 10.1308/003588408X286035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Shu X, Hildebrandt MA, Gu J, Tannir NM, Matin SF, Karam JA, Wood CG, Wu X. MicroRNA profiling in clear cell renal cell carcinoma tissues potentially links tumorigenesis and recurrence with obesity. Br J Cancer 2017;116:77-84. [PMID: 27907930 DOI: 10.1038/bjc.2016.392] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
7 Shi D, Qu Q, Chang Q, Wang Y, Gui Y, Dong D. A five-long non-coding RNA signature to improve prognosis prediction of clear cell renal cell carcinoma. Oncotarget. 2017;8:58699-58708. [PMID: 28938589 DOI: 10.18632/oncotarget.17506] [Cited by in Crossref: 20] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
8 Hu SL, Chang A, Perazella MA, Okusa MD, Jaimes EA, Weiss RH; American Society of Nephrology Onco-Nephrology Forum. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol 2016;27:2227-37. [PMID: 26961346 DOI: 10.1681/ASN.2015121335] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
9 Gao Z, Chen J, Tao Y, Wang Q, Peng S, Yu S, Zeng J, Li K, Xie Z, Huang H. Immune Signatures Combined With BRCA1-Associated Protein 1 Mutations Predict Prognosis and Immunotherapy Efficacy in Clear Cell Renal Cell Carcinoma. Front Cell Dev Biol 2021;9:747985. [PMID: 34733850 DOI: 10.3389/fcell.2021.747985] [Reference Citation Analysis]
10 Li H, Wang J, Wei Q, Wang H. Simultaneous metastases of clear cell renal cell carcinoma to the urinary bladder and left retroperitoneal space: A case report and review of the literature. Oncol Lett 2016;12:167-70. [PMID: 27347119 DOI: 10.3892/ol.2016.4579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Brookman-Amissah S, May M, Albrecht K, Herrmann T, Roigas J, Gilfrich CP, Pflanz S, Gunia S. Urinary collecting system invasion reflects adverse long-term outcome and is associated with simultaneous metastatic spread at the time of surgery and with multilocular dissemination during postsurgical follow-up in renal cell cancer. World J Urol 2010;28:103-9. [PMID: 19479264 DOI: 10.1007/s00345-009-0426-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
12 Zhao H, Zhang J, Fu X, Mao D, Qi X, Liang S, Meng G, Song Z, Yang R, Guo Z, Tong B, Sun M, Zuo B, Li G. Integrated bioinformatics analysis of the NEDD4 family reveals a prognostic value of NEDD4L in clear-cell renal cell cancer. PeerJ 2021;9:e11880. [PMID: 34458018 DOI: 10.7717/peerj.11880] [Reference Citation Analysis]
13 Kassouf W, Siemens R, Morash C, Lacombe L, Jewett M, Goldenberg L, Chin J, Chetner M, Wood CG, Tanguay S, Aprikian AG. Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J 2009;3:73-6. [PMID: 19293984 DOI: 10.5489/cuaj.1028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 29] [Article Influence: 2.2] [Reference Citation Analysis]
14 Tamura K, Horikawa M, Sato S, Miyake H, Setou M. Discovery of lipid biomarkers correlated with disease progression in clear cell renal cell carcinoma using desorption electrospray ionization imaging mass spectrometry. Oncotarget 2019;10:1688-703. [PMID: 30899441 DOI: 10.18632/oncotarget.26706] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
15 Najjar YG, Rini BI. Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol 2012;4:183-94. [PMID: 22754592 DOI: 10.1177/1758834012443725] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.1] [Reference Citation Analysis]
16 Bassanelli M, Borro M, Roberto M, Giannarelli D, Giacinti S, Di Martino S, Ceribelli A, Russo A, Aschelter A, Scarpino S, Montori A, Pescarmona E, Tomao S, Simmaco M, Cognetti F, Milella M, Marchetti P. A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;14:178. [PMID: 35008342 DOI: 10.3390/cancers14010178] [Reference Citation Analysis]
17 Stenehjem DD, Hahn AW, Gill DM, Albertson D, Gowrishankar B, Merriman J, Agarwal AM, Thodima V, Harrington EB, Au TH, Maughan BL, Houldsworth J, Pal SK, Agarwal N. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. PLoS One 2019;14:e0210415. [PMID: 30682039 DOI: 10.1371/journal.pone.0210415] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Wang C, Wang G, Zhang Z, Wang Z, Ren M, Wang X, Li H, Yu Y, Liu J, Cai L, Li Y, Zhang D, Zhang C. The downregulated long noncoding RNA DHRS4-AS1 is protumoral and associated with the prognosis of clear cell renal cell carcinoma. Onco Targets Ther 2018;11:5631-46. [PMID: 30254456 DOI: 10.2147/OTT.S164984] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
19 Bratslavsky G, Linehan WM. Long-term management of bilateral, multifocal, recurrent renal carcinoma. Nat Rev Urol 2010;7:267-75. [PMID: 20448660 DOI: 10.1038/nrurol.2010.44] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
20 Singla N, Xie Z, Zhang Z, Gao M, Yousuf Q, Onabolu O, McKenzie T, Tcheuyap VT, Ma Y, Choi J, McKay R, Christie A, Torras OR, Bowman IA, Margulis V, Pedrosa I, Przybycin C, Wang T, Kapur P, Rini B, Brugarolas J. Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight 2020;5:134564. [PMID: 32271170 DOI: 10.1172/jci.insight.134564] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
21 Zhang X, Sun G, Zhao J, Shu K, Zhao P, Liu J, Yang Y, Tang Q, Chen J, Shen P, Wang J, Zeng H. Improved Long-Term Clinical Outcomes And Safety Profile Of Sunitinib Dosing Schedule With 4/2 Switched To 2/1 In Patients With Metastatic Renal Cell Carcinoma. J Cancer 2018;9:3303-10. [PMID: 30271490 DOI: 10.7150/jca.25693] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
22 Kim MC, Jin Z, Kolb R, Borcherding N, Chatzkel JA, Falzarano SM, Zhang W. Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma. Cancers (Basel) 2021;13:5856. [PMID: 34831009 DOI: 10.3390/cancers13225856] [Reference Citation Analysis]
23 Maroto P, Esteban E, Parra EF, Mendez-Vidal MJ, Domenech M, Pérez-Valderrama B, Calderero V, Pérez-Gracia JL, Grande E, Algaba F. HIF pathway and c-Myc as biomarkers for response to sunitinib in metastatic clear-cell renal cell carcinoma. Onco Targets Ther 2017;10:4635-43. [PMID: 29033582 DOI: 10.2147/OTT.S137677] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
24 Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8. [PMID: 28967554 DOI: 10.1016/j.eururo.2017.09.008] [Cited by in Crossref: 68] [Cited by in F6Publishing: 81] [Article Influence: 13.6] [Reference Citation Analysis]
25 Sameh WM, Hashad MM, Eid AA, Abou Yousif TA, Atta MA. Recurrence pattern in patients with locally advanced renal cell carcinoma: The implications of clinicopathological variables. Arab J Urol 2012;10:131-7. [PMID: 26558015 DOI: 10.1016/j.aju.2011.12.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
26 Chen JB, Yang HS, Moi SH, Chuang LY, Yang CH. Identification of mortality-risk-related missense variant for renal clear cell carcinoma using deep learning. Ther Adv Chronic Dis 2021;12:2040622321992624. [PMID: 33643601 DOI: 10.1177/2040622321992624] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Jain S, Yates JK, Munver R. Robot-Assisted Laparoscopic Partial Nephrectomy for Recurrent Renal-Cell Carcinoma in Patients Previously Treated with Nephron-Sparing Surgery. Journal of Endourology 2013;27:309-12. [DOI: 10.1089/end.2012.0184] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
28 Cho IC, Chung J. Current status of targeted therapy for advanced renal cell carcinoma. Korean J Urol 2012;53:217-28. [PMID: 22536463 DOI: 10.4111/kju.2012.53.4.217] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
29 Cao G, Wu X, Wang Z, Tian X, Zhang C, Wu X, Zhang H, Jing G, Yan T. What is the optimum systemic treatment for advanced/metastatic renal cell carcinoma of favourable, intermediate and poor risk, respectively? A systematic review and network meta-analysis. BMJ Open 2020;10:e034626. [PMID: 32859659 DOI: 10.1136/bmjopen-2019-034626] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Vornicova O, Bar-Sela G. Do we have a "game changer" in treating patients with brain metastasis from renal cell carcinoma? Ann Transl Med 2019;7:S360. [PMID: 32016078 DOI: 10.21037/atm.2019.09.50] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Zhang L, Wang X, Bullock AJ, Callea M, Shah H, Song J, Moreno K, Visentin B, Deutschman D, Alsop DC, Atkins MB, Mier JW, Signoretti S, Bhasin M, Sabbadini RA, Bhatt RS. Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clin Cancer Res 2015;21:1925-34. [PMID: 25589614 DOI: 10.1158/1078-0432.CCR-14-2031] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
32 DeVoe WB, Kercher KW, Hope WW, Lincourt AE, Norton HJ, Teigland CM. Hand-assisted laparoscopic partial nephrectomy after 60 cases: comparison with open partial nephrectomy. Surg Endosc 2009;23:1075-80. [PMID: 18830753 DOI: 10.1007/s00464-008-0135-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
33 Trilla-Fuertes L, Miranda N, Castellano D, López-Vacas R, Farfán Tello CA, de Velasco G, Villacampa F, López-Camacho E, Prado-Vázquez G, Zapater-Moros A, Espinosa E, Fresno Vara JÁ, Pinto Á, Gámez-Pozo A. miRNA profiling in renal carcinoma suggest the existence of a group of pro-angionenic tumors in localized clear cell renal carcinoma. PLoS One 2020;15:e0229075. [PMID: 32109249 DOI: 10.1371/journal.pone.0229075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Chiu IJ, Hsu YH, Chang JS, Yang JC, Chiu HW, Lin YF. Lactotransferrin Downregulation Drives the Metastatic Progression in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2020;12:E847. [PMID: 32244557 DOI: 10.3390/cancers12040847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
35 Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY. Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Res Treat 2009;41:67-72. [PMID: 19707503 DOI: 10.4143/crt.2009.41.2.67] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
36 Kakizoe M, Yao M, Tateishi U, Minamimoto R, Ueno D, Namura K, Makiyama K, Hayashi N, Sano F, Kishida T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Taguri M, Morita S, Inoue T, Kubota Y, Nakaigawa N. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. BMC Cancer 2014;14:390. [PMID: 24885730 DOI: 10.1186/1471-2407-14-390] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
37 Gadd M, Pranavan G, Malik L. Association between tyrosine-kinase inhibitor induced hypertension and treatment outcomes in metastatic renal cancer. Cancer Rep (Hoboken) 2020;3:e1275. [PMID: 32767664 DOI: 10.1002/cnr2.1275] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Bergerot PG, Hahn AW, Bergerot CD, Jones J, Pal SK. The Role of Circulating Tumor DNA in Renal Cell Carcinoma. Curr Treat Options Oncol 2018;19:10. [PMID: 29464405 DOI: 10.1007/s11864-018-0530-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
39 Hu X, Yang ZQ, Dou WC, Shao YX, Wang YH, Lia T, Li X. Validation of the Prognostic Value of Preoperative Albumin-to-Alkaline Phosphatase Ratio in Patients with Surgically Treated Non-Metastatic Renal Cell Carcinoma. Onco Targets Ther 2020;13:8287-97. [PMID: 32903862 DOI: 10.2147/OTT.S264217] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
40 Ippen FM, Mahadevan A, Wong ET, Uhlmann EJ, Sengupta S, Kasper EM. Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection. J Oncol 2015;2015:636918. [PMID: 26681942 DOI: 10.1155/2015/636918] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
41 Mikami S, Oya M, Mizuno R, Kosaka T, Katsube K, Okada Y. Invasion and metastasis of renal cell carcinoma. Med Mol Morphol 2014;47:63-7. [PMID: 24213520 DOI: 10.1007/s00795-013-0064-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
42 Karakatsanis A, Vezakis A, Fragulidis G, Staikou C, Carvounis EE, Polydorou A. Obstructive jaundice due to ampullary metastasis of renal cell carcinoma. World J Surg Oncol 2013;11:262. [PMID: 24099455 DOI: 10.1186/1477-7819-11-262] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
43 Dion M, Martínez CH, Williams AK, Chalasani V, Nott L, Pautler SE. Cost analysis of two follow-up strategies for localized kidney cancer: a Canadian cohort comparison. Can Urol Assoc J 2010;4:322-6. [PMID: 20944802 DOI: 10.5489/cuaj.10017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
44 Motzer RJ, Escudier B, Gannon A, Figlin RA. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma. Oncologist 2017;22:41-52. [PMID: 27807302 DOI: 10.1634/theoncologist.2016-0197] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
45 Pankowska V, Malkowski B, Wedrowski M, Wedrowska E, Roszkowski K. FDG PET/CT as a survival prognostic factor in patients with advanced renal cell carcinoma. Clin Exp Med 2019;19:143-8. [PMID: 30488140 DOI: 10.1007/s10238-018-0539-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
46 Öztürk H. Genetic architecture of renal cell carcinoma: Do we have to know? World J Urol 2016;34:765-9. [PMID: 26412087 DOI: 10.1007/s00345-015-1697-y] [Reference Citation Analysis]
47 Fiasconaro E, Caobelli F, Quartuccio N, Messina M, Spada M, Albano D, Alongi P. PET/CT for the diagnostic assessment of patients with renal cancer. Clin Transl Imaging 2018;6:207-16. [DOI: 10.1007/s40336-018-0278-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Ordikhani F, Kasinath V, Uehara M, Akbarzadeh A, Yilmam OA, Dai L, Aksu H, Jung S, Jiang L, Li X, Zhao J, Bahmani B, Ichimura T, Fiorina P, Annabi N, Abdi R. Selective Trafficking of Light Chain-Conjugated Nanoparticles to the Kidney and Renal Cell Carcinoma. Nano Today 2020;35:100990. [PMID: 33244320 DOI: 10.1016/j.nantod.2020.100990] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Speed JM, Trinh QD, Choueiri TK, Sun M. Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data. Curr Urol Rep. 2017;18:15. [PMID: 28213859 DOI: 10.1007/s11934-017-0661-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
50 Patel HV, Srivastava A, Shinder B, Sadimin E, Singer EA. Strengthening the foundation of kidney cancer treatment and research: revising the AJCC staging system. Ann Transl Med 2019;7:S33. [PMID: 31032312 DOI: 10.21037/atm.2019.02.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
51 Nizioł J, Sunner J, Beech I, Ossoliński K, Ossolińska A, Ossoliński T, Płaza A, Ruman T. Localization of Metabolites of Human Kidney Tissue with Infrared Laser-Based Selected Reaction Monitoring Mass Spectrometry Imaging and Silver-109 Nanoparticle-Based Surface Assisted Laser Desorption/Ionization Mass Spectrometry Imaging. Anal Chem 2020;92:4251-8. [PMID: 32083846 DOI: 10.1021/acs.analchem.9b04580] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
52 Yin Q, Hung SC, Rathmell WK, Shen L, Wang L, Lin W, Fielding JR, Khandani AH, Woods ME, Milowsky MI, Brooks SA, Wallen EM, Shen D. Integrative radiomics expression predicts molecular subtypes of primary clear cell renal cell carcinoma. Clin Radiol 2018;73:782-91. [PMID: 29801658 DOI: 10.1016/j.crad.2018.04.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
53 Roldán FL, Lozano JJ, Ingelmo-Torres M, Carrasco R, Díaz E, Ramirez-Backhaus M, Rubio J, Reig O, Alcaraz A, Mengual L, Izquierdo L. Clinicopathological and Molecular Prognostic Classifier for Intermediate/High-Risk Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;13:6338. [PMID: 34944958 DOI: 10.3390/cancers13246338] [Reference Citation Analysis]
54 Wang Z, Peng S, Jiang N, Wang A, Liu S, Xie H, Guo L, Cai Q, Niu Y. Prognostic and clinicopathological value of p53 expression in renal cell carcinoma: a meta-analysis. Oncotarget 2017;8:102361-70. [PMID: 29254251 DOI: 10.18632/oncotarget.21971] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
55 Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer 2010;10:667. [PMID: 21129184 DOI: 10.1186/1471-2407-10-667] [Cited by in Crossref: 61] [Cited by in F6Publishing: 53] [Article Influence: 5.1] [Reference Citation Analysis]
56 Seliger B, Jasinski S, Dressler SP, Marincola FM, Recktenwald CV, Wang E, Lichtenfels R. Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? J Proteome Res 2011;10:191-9. [PMID: 21142213 DOI: 10.1021/pr1011137] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
57 Zall H, Weber A, Besch R, Zantl N, Häcker G. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer 2010;9:164. [PMID: 20576107 DOI: 10.1186/1476-4598-9-164] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.0] [Reference Citation Analysis]
58 Krajewski KM, Nishino M, Franchetti Y, Ramaiya NH, Van den Abbeele AD, Choueiri TK. Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer. 2014;120:711-721. [PMID: 24264883 DOI: 10.1002/cncr.28493] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
59 Milanetto AC, Morelli L, Di Franco G, David A, Campra D, De Paolis P, Pasquali C. A Plea for Surgery in Pancreatic Metastases from Renal Cell Carcinoma: Indications and Outcome from a Multicenter Surgical Experience. J Clin Med 2020;9:E3278. [PMID: 33066168 DOI: 10.3390/jcm9103278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Ballarin R, Spaggiari M, Cautero N, Ruvo ND, Montalti R, Longo C, Pecchi A, Giacobazzi P, Marco GD, D’Amico G, Gerunda GE, Benedetto FD. Pancreatic metastases from renal cell carcinoma: The state of the art. World J Gastroenterol 2011; 17(43): 4747-4756 [PMID: 22147975 DOI: 10.3748/wjg.v17.i43.4747] [Cited by in CrossRef: 94] [Cited by in F6Publishing: 78] [Article Influence: 8.5] [Reference Citation Analysis]
61 Nakaigawa N, Kondo K, Tateishi U, Minamimoto R, Kaneta T, Namura K, Ueno D, Kobayashi K, Kishida T, Ikeda I, Hasumi H, Makiyama K, Kubota Y, Inoue T, Yao M. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. BMC Cancer 2016;16:67. [PMID: 26857818 DOI: 10.1186/s12885-016-2097-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
62 Marchand Crety C, Vigneau E, Invernizzi C. Stereotactic Body Radiotherapy of a Solitary Metachronous Sphenoid Metastasis from Renal Cell Cancer: A Case Report. Case Rep Oncol 2021;14:269-73. [PMID: 33776715 DOI: 10.1159/000513743] [Reference Citation Analysis]
63 Kim H, Lee SJ, Park SJ, Choi IY, Hong SH. Machine Learning Approach to Predict the Probability of Recurrence of Renal Cell Carcinoma After Surgery: Prediction Model Development Study. JMIR Med Inform 2021;9:e25635. [PMID: 33646127 DOI: 10.2196/25635] [Reference Citation Analysis]
64 Chen YH, Wu XR, Hu ZL, Wang WJ, Jiang C, Kong W, Chen W, Xue W, Liu DM, Huang YR. Treatment of renal cell carcinoma with a level III or level IV inferior vena cava thrombus using cardiopulmonary bypass and deep hypothermic circulatory arrest. World J Surg Oncol 2015;13:159. [PMID: 25897659 DOI: 10.1186/s12957-015-0584-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
65 Suwaki N, Vanhecke E, Atkins KM, Graf M, Swabey K, Huang P, Schraml P, Moch H, Cassidy AM, Brewer D, Al-Lazikani B, Workman P, De-Bono J, Kaye SB, Larkin J, Gore ME, Sawyers CL, Nelson P, Beer TM, Geng H, Gao L, Qian DZ, Alumkal JJ, Thomas G, Thomas GV. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma. Sci Transl Med 2011;3:85ra47. [PMID: 21632985 DOI: 10.1126/scitranslmed.3002004] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
66 Mitchell CC, Parikh OA. Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib. Patient Prefer Adherence 2014;8:503-11. [PMID: 24790418 DOI: 10.2147/PPA.S38989] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
67 Keizman D, Huang P, Eisenberger MA, Pili R, Kim JJ, Antonarakis ES, Hammers H, Carducci MA. Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination. Eur J Cancer 2011;47:1955-61. [PMID: 21600760 DOI: 10.1016/j.ejca.2011.04.019] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 7.2] [Reference Citation Analysis]
68 Atrih A, Mudaliar MA, Zakikhani P, Lamont DJ, Huang JT, Bray SE, Barton G, Fleming S, Nabi G. Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling. Br J Cancer 2014;110:1622-33. [PMID: 24548857 DOI: 10.1038/bjc.2014.24] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
69 Lourenço C, Constâncio V, Henrique R, Carvalho Â, Jerónimo C. Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances. Cancers (Basel) 2021;13:1529. [PMID: 33810357 DOI: 10.3390/cancers13071529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12. [PMID: 15812574 DOI: 10.1007/s00345-004-0466-0] [Cited by in Crossref: 159] [Cited by in F6Publishing: 139] [Article Influence: 9.4] [Reference Citation Analysis]
71 Anwar SM, Kalbi DP, Upadhyaya A, Aqsa A, Mukherjee I. Scoping Renal Cell Carcinoma in the Rectal and Anal Canal: A Literature Review. Cureus 2019;11:e6330. [PMID: 31938620 DOI: 10.7759/cureus.6330] [Reference Citation Analysis]
72 Tosoian JJ, Cameron JL, Allaf ME, Hruban RH, Nahime CB, Pawlik TM, Pierorazio PM, Reddy S, Wolfgang CL. Resection of isolated renal cell carcinoma metastases of the pancreas: outcomes from the Johns Hopkins Hospital. J Gastrointest Surg 2014;18:542-8. [PMID: 24163138 DOI: 10.1007/s11605-013-2278-2] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
73 Evangelista L, Zattoni F, Alongi P. 68Ga-dotatoc vs. 18F-FDG vs. radiolabelled PSMA PET/CT in renal cancer patients. Ann Transl Med 2019;7:S150. [PMID: 31576357 DOI: 10.21037/atm.2019.06.28] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Hellbach K, Sterzik A, Sommer W, Karpitschka M, Hummel N, Casuscelli J, Ingrisch M, Schlemmer M, Graser A, Staehler M. Dual energy CT allows for improved characterization of response to antiangiogenic treatment in patients with metastatic renal cell cancer. Eur Radiol 2017;27:2532-7. [PMID: 27678131 DOI: 10.1007/s00330-016-4597-7] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
75 Wang B, Gu W, Wan F, Shi G, Ye D. Prognostic significance of the dynamic changes of systemic inflammatory response in metastatic renal cell carcinoma. Int Braz J Urol 2019;45:89-99. [PMID: 29570259 DOI: 10.1590/S1677-5538.IBJU.2017.0500] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
76 Song S, Long M, Yu G, Cheng Y, Yang Q, Liu J, Wang Y, Sheng J, Wang L, Wang Z, Xu B. Urinary exosome miR-30c-5p as a biomarker of clear cell renal cell carcinoma that inhibits progression by targeting HSPA5. J Cell Mol Med 2019;23:6755-65. [PMID: 31342628 DOI: 10.1111/jcmm.14553] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
77 Wang J, Al-Lamki RS. Tumor necrosis factor receptor 2: its contribution to acute cellular rejection and clear cell renal carcinoma. Biomed Res Int 2013;2013:821310. [PMID: 24350291 DOI: 10.1155/2013/821310] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
78 Markowitsch SD, Schupp P, Lauckner J, Vakhrusheva O, Slade KS, Mager R, Efferth T, Haferkamp A, Juengel E. Artesunate Inhibits Growth of Sunitinib-Resistant Renal Cell Carcinoma Cells through Cell Cycle Arrest and Induction of Ferroptosis. Cancers (Basel) 2020;12:E3150. [PMID: 33121039 DOI: 10.3390/cancers12113150] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
79 Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, Stanton ML, Hodi FS, McDermott DF, Atkins MB, Freeman GJ, Hirsch MS, Signoretti S. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol 2014;25:2178-84. [PMID: 25193987 DOI: 10.1093/annonc/mdu445] [Cited by in Crossref: 179] [Cited by in F6Publishing: 178] [Article Influence: 22.4] [Reference Citation Analysis]
80 Nerich V, Hugues M, Paillard MJ, Borowski L, Nai T, Stein U, Nguyen Tan Hon T, Montcuquet P, Maurina T, Mouillet G, Kleinclauss F, Pivot X, Limat S, Thiery-Vuillemin A. Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. Onco Targets Ther 2014;7:365-74. [PMID: 24600236 DOI: 10.2147/OTT.S56370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 11] [Article Influence: 3.1] [Reference Citation Analysis]
81 Wang Z, Xie H, Guo L, Cai Q, Shang Z, Jiang N, Niu Y. Prognostic and clinicopathological value of Ki-67/MIB-1 expression in renal cell carcinoma: a meta-analysis based on 4579 individuals. Cancer Manag Res 2017;9:679-89. [PMID: 29200888 DOI: 10.2147/CMAR.S141670] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
82 Deng H, Huang Y, Hong Z, Yuan X, Cao Z, Wei Y, Zhang W. Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis. BMC Cancer 2019;19:489. [PMID: 31122210 DOI: 10.1186/s12885-019-5704-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
83 Chow S, Galvis V, Pillai M, Leach R, Keene E, Spencer-Shaw A, Shablak A, Shanks J, Liptrot T, Thistlethwaite F, Hawkins RE. High-dose interleukin2 - a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome. J Immunother Cancer 2016;4:67. [PMID: 27777776 DOI: 10.1186/s40425-016-0174-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
84 Shinder BM, Rhee K, Farrell D, Farber NJ, Stein MN, Jang TL, Singer EA. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Front Oncol. 2017;7:107. [PMID: 28620578 DOI: 10.3389/fonc.2017.00107] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
85 Schmidinger M, Zielinski CC. Defining risk status in the first-line treatment of metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2010;136:961-8. [PMID: 20454802 DOI: 10.1007/s00432-010-0901-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
86 Kim MS, Chung HS, Hwang EC, Jung SI, Kwon DD, Hwang JE, Bae WK, Park JY, Jeong CW, Kwak C, Song C, Seo SI, Byun SS, Hong SH, Chung J. Efficacy of First-Line Targeted Therapy in Real-World Korean Patients with Metastatic Renal Cell Carcinoma: Focus on Sunitinib and Pazopanib. J Korean Med Sci 2018;33:e325. [PMID: 30546281 DOI: 10.3346/jkms.2018.33.e325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
87 Kis B, Shah J, Choi J, El-Haddad G, Sweeney J, Biebel B, Mellon E, Frakes JM, Hoffe SE, Fishman MN, Shridhar R. Transarterial Yttrium-90 Radioembolization Treatment of Patients with Liver-Dominant Metastatic Renal Cell Carcinoma. J Vasc Interv Radiol 2017;28:254-9. [PMID: 27955832 DOI: 10.1016/j.jvir.2016.09.025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
88 Mielczarek Ł, Brodziak A, Sobczuk P, Kawecki M, Cudnoch-Jędrzejewska A, Czarnecka AM. Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function. Cancer Chemother Pharmacol 2021;87:723-42. [PMID: 33768301 DOI: 10.1007/s00280-021-04260-y] [Reference Citation Analysis]
89 Jin Y, Liu J, Liu Y, Liu Y, Guo G, Yu S, An R. Oxymatrine Inhibits Renal Cell Carcinoma Progression by Suppressing β-Catenin Expression. Front Pharmacol 2020;11:808. [PMID: 32581789 DOI: 10.3389/fphar.2020.00808] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Wu Y, Zhao Y. Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. Int J Urol 2011;18:430-1. [PMID: 21599760 DOI: 10.1111/j.1442-2042.2011.02770.x] [Reference Citation Analysis]
91 Schneider G, Probst T, Kirchin MA, Stroeder J, Fries P, Buecker A. Low-dose gadobenate dimeglumine-enhanced MRI of the kidney for the differential diagnosis of localized renal lesions. Radiol Med 2015;120:1100-11. [PMID: 26088468 DOI: 10.1007/s11547-015-0548-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
92 Audenet F, Rouprêt M, Méjean A. [Renal cell carcinoma and antiangiogenic agents: ongoing controversies are seeking answers for improvement of therapeutic management]. Prog Urol 2009;19:596-605. [PMID: 19800548 DOI: 10.1016/j.purol.2009.05.009] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
93 Zhu J, Zhu Y, Qi W, Qiu W. Effects of the novel heat shock protein 90 inhibitor AUY922 in renal cell carcinoma ACHN and 786-O cells. Oncol Lett 2015;10:941-5. [PMID: 26622600 DOI: 10.3892/ol.2015.3299] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
94 Kempkensteffen C, Hinz S, Christoph F, Krause H, Magheli A, Schrader M, Schostak M, Miller K, Weikert S. Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value. J Cancer Res Clin Oncol. 2008;134:543-550. [PMID: 17922292 DOI: 10.1007/s00432-007-0317-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
95 Oserowsky A, Allison D, Weinstein S, Nguyen V, Murray KS. Metastasis of renal cell carcinoma to the distal ureteral stump beyond recommended baseline surveillance duration. Urol Case Rep 2020;32:101266. [PMID: 32489889 DOI: 10.1016/j.eucr.2020.101266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
96 Su Z, Chen D, Li Y, Zhang E, Yu Z, Chen T, Jiang Z, Ni L, Yang S, Gui Y, Ye J, Lai Y. microRNA-184 functions as tumor suppressor in renal cell carcinoma. Exp Ther Med 2015;9:961-6. [PMID: 25667660 DOI: 10.3892/etm.2015.2199] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
97 Czarnecka AM, Brodziak A, Sobczuk P, Dendek C, Labochka D, Korniluk J, Bartnik E, Szczylik C. Metastatic Tumor Burden and Loci as Predictors of First Line Sunitinib Treatment Efficacy in Patients with Renal Cell Carcinoma. Sci Rep 2019;9:7754. [PMID: 31123336 DOI: 10.1038/s41598-019-44226-y] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
98 Bourlon MT, Gao D, Trigero S, Clemons JE, Breaker K, Lam ET, Flaig TW. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma. Cancer Med 2016;5:3386-93. [PMID: 27758076 DOI: 10.1002/cam4.919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
99 Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010;31:1805-12. [PMID: 20732906 DOI: 10.1093/carcin/bgq168] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 7.9] [Reference Citation Analysis]
100 Shang D, Xu X, Wang D, Li Y, Liu Y. Protein tyrosine phosphatase ζ enhances proliferation by increasing β-catenin nuclear expression in VHL-inactive human renal cell carcinoma cells. World J Urol 2013;31:1547-54. [PMID: 23588815 DOI: 10.1007/s00345-013-1077-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
101 Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, Baneyx G, Banerjee H, Aimone P, Motzer RJ. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clin Cancer Res 2018;24:3005-13. [PMID: 29330204 DOI: 10.1158/1078-0432.CCR-17-2652] [Cited by in Crossref: 34] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
102 Cecere SC, Rossetti S, Cavaliere C, Della Pepa C, Di Napoli M, Crispo A, Iovane G, Piscitelli R, Sorrentino D, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Pignata S, Facchini G, D'Aniello C. Pazopanib in Metastatic Renal Cancer: A "Real-World" Experience at National Cancer Institute "Fondazione G. Pascale". Front Pharmacol 2016;7:287. [PMID: 27630568 DOI: 10.3389/fphar.2016.00287] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
103 Gill DM, Hahn AW, Hale P, Maughan BL. Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. Curr Treat Options Oncol 2018;19:6. [PMID: 29368125 DOI: 10.1007/s11864-018-0517-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
104 Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int. 2016;117:761-765. [PMID: 26032863 DOI: 10.1111/bju.13185] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
105 Laird A, O'Mahony FC, Nanda J, Riddick AC, O'Donnell M, Harrison DJ, Stewart GD. Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PLoS One 2013;8:e60483. [PMID: 23577117 DOI: 10.1371/journal.pone.0060483] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
106 Wu S, Wang Y, Sun L, Zhang Z, Jiang Z, Qin Z, Han H, Liu Z, Li X, Tang A, Gui Y, Cai Z, Zhou F. Decreased expression of dual-specificity phosphatase 9 is associated with poor prognosis in clear cell renal cell carcinoma. BMC Cancer 2011;11:413. [PMID: 21943117 DOI: 10.1186/1471-2407-11-413] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
107 Tabei T, Nakaigawa N, Kaneta T, Ikeda I, Kondo K, Makiyama K, Hasumi H, Hayashi N, Kawahara T, Izumi K, Osaka K, Muraoka K, Teranishi JI, Miyoshi Y, Yumura Y, Uemura H, Kobayashi K, Inoue T, Yao M. Early assessment with 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography to predict short-term outcome in clear cell renal carcinoma treated with nivolumab. BMC Cancer 2019;19:298. [PMID: 30940117 DOI: 10.1186/s12885-019-5510-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
108 Adamowicz J, Tworkiewicz J, Siekiera J, Drewa T. Ablative therapies for small renal tumors. Contemp Oncol (Pozn) 2013;17:24-8. [PMID: 23788957 DOI: 10.5114/wo.2013.33770] [Reference Citation Analysis]
109 Cros J, Sbidian E, Posseme K, Letierce A, Guettier C, Benoît G, Ferlicot S. Nestin expression on tumour vessels and tumour-infiltrating macrophages define a poor prognosis subgroup of pt1 clear cell renal cell carcinoma. Virchows Arch 2016;469:331-7. [PMID: 27311769 DOI: 10.1007/s00428-016-1973-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
110 Cai Q, Christie A, Rajaram S, Zhou Q, Araj E, Chintalapati S, Cadeddu J, Margulis V, Pedrosa I, Rakheja D, McKay RM, Brugarolas J, Kapur P. Ontological analyses reveal clinically-significant clear cell renal cell carcinoma subtypes with convergent evolutionary trajectories into an aggressive type. EBioMedicine 2020;51:102526. [PMID: 31859241 DOI: 10.1016/j.ebiom.2019.10.052] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
111 Hawkins R, Fife K, Hurst M, Wang M, Naicker N, Nolasco S, Eisen T, Matakidou A, Gordon J. Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK. BMC Cancer 2020;20:670. [PMID: 32680483 DOI: 10.1186/s12885-020-07154-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
112 Xing Q, Ji C, Zhu B, Cong R, Wang Y. Identification of small molecule drugs and development of a novel autophagy-related prognostic signature for kidney renal clear cell carcinoma. Cancer Med 2020;9:7034-51. [PMID: 32780567 DOI: 10.1002/cam4.3367] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
113 Lin ZZ, Ming DS, Chen YB, Zhang JM, Chen HH, Jiang JJ, Zhang ZS. KMT5A promotes metastasis of clear cell renal cell carcinoma through reducing cadherin-1 expression. Oncol Lett 2019;17:4907-13. [PMID: 31186699 DOI: 10.3892/ol.2019.10163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
114 Kim KS, Sekar RR, Patil D, Dimarco MA, Kissick HT, Bilen MA, Osunkoya AO, Master VA. Evaluation of programmed cell death protein 1 (PD-1) expression as a prognostic biomarker in patients with clear cell renal cell carcinoma. Oncoimmunology 2018;7:e1413519. [PMID: 29632730 DOI: 10.1080/2162402X.2017.1413519] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
115 Abel EJ, Wood CG. Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 2009;6:375-383. [PMID: 19528960 DOI: 10.1038/nrurol.2009.102] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
116 Zeng Z, Que T, Zhang J, Hu Y. A study exploring critical pathways in clear cell renal cell carcinoma. Exp Ther Med 2014;7:121-30. [PMID: 24348776 DOI: 10.3892/etm.2013.1392] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
117 Carrafiello G, Dionigi G, Boni L, Mangini M, Ierardi AM, Piacentino F, Di Massa A, Nocchi Cardim L, Biondi A, Fugazzola C. Current role of interventions in metastatic kidney tumors: single center experience. Updates Surg 2011;63:259-69. [PMID: 22065381 DOI: 10.1007/s13304-011-0118-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
118 Quivy A, Daste A, Harbaoui A, Duc S, Bernhard JC, Gross-Goupil M, Ravaud A. Optimal management of renal cell carcinoma in the elderly: a review. Clin Interv Aging 2013;8:433-42. [PMID: 23626463 DOI: 10.2147/CIA.S30765] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
119 Chatzizacharias NA, Rosich-Medina A, Dajani K, Harper S, Huguet E, Liau SS, Praseedom RK, Jah A. Surgical management of hepato-pancreatic metastasis from renal cell carcinoma. World J Gastrointest Oncol 2017; 9(2): 70-77 [PMID: 28255428 DOI: 10.4251/wjgo.v9.i2.70] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
120 Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol 2017;35:3916-23. [PMID: 28902533 DOI: 10.1200/JCO.2017.73.5324] [Cited by in Crossref: 181] [Cited by in F6Publishing: 80] [Article Influence: 36.2] [Reference Citation Analysis]
121 Kim JM, Song PH, Kim HT, Park TC. The Prognostic Factors for Patients with pT1a Renal Cell Carcinoma. Korean J Urol 2010;51:233-8. [PMID: 20428424 DOI: 10.4111/kju.2010.51.4.233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
122 Nakaigawa N, Kondo K, Ueno D, Namura K, Makiyama K, Kobayashi K, Shioi K, Ikeda I, Kishida T, Kaneta T, Minamimoto R, Tateishi U, Inoue T, Yao M. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy. BMC Cancer 2017;17:39. [PMID: 28068944 DOI: 10.1186/s12885-016-3044-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
123 Flörcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Jöhrens K, Möbs M, Schönemann C, Sawitzki B, Egerer K, Dörken B, Pezzutto A, Westermann J. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Hum Vaccin Immunother 2013;9:1217-27. [PMID: 23458999 DOI: 10.4161/hv.24149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
124 Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, Stief CG, Jauch KW, Bruns CJ. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010;28:543-547. [PMID: 20440505 DOI: 10.1007/s00345-010-0560-4] [Cited by in Crossref: 92] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
125 De Luca R, Gouyou B, Ongaro T, Villa A, Ziffels B, Sannino A, Buttinoni G, Galeazzi S, Mazzacuva M, Neri D. A Novel Fully-Human Potency-Matched Dual Cytokine-Antibody Fusion Protein Targets Carbonic Anhydrase IX in Renal Cell Carcinomas. Front Oncol 2019;9:1228. [PMID: 31799191 DOI: 10.3389/fonc.2019.01228] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
126 Sun M, Choueiri TK. Kidney cancer: Recurrence in renal cell carcinoma: the work is not done. Nat Rev Urol 2016;13:246-7. [PMID: 27030528 DOI: 10.1038/nrurol.2016.57] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
127 Keizman D, Gottfried M, Ish-Shalom M, Maimon N, Peer A, Neumann A, Hammers H, Eisenberger MA, Sinibaldi V, Pili R, Hayat H, Kovel S, Sella A, Boursi B, Weitzen R, Mermershtain W, Rouvinov K, Berger R, Carducci MA. Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 2014;19:51-60. [PMID: 24309979 DOI: 10.1634/theoncologist.2012-0335] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
128 El-Mokadem I, Fitzpatrick J, Rai B, Cunningham J, Pratt N, Fleming S, Nabi G. Significance of chromosome 9p status in renal cell carcinoma: a systematic review and quality of the reported studies. Biomed Res Int 2014;2014:521380. [PMID: 24877109 DOI: 10.1155/2014/521380] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
129 Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths DF. Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer 2008;98:931-40. [PMID: 18283322 DOI: 10.1038/sj.bjc.6604243] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
130 Wu XR, Chen YH, Liu DM, Sha JJ, Xuan HQ, Bo JJ, Huang YR. Increased expression of forkhead box M1 protein is associated with poor prognosis in clear cell renal cell carcinoma. Med Oncol 2013;30:346. [PMID: 23263830 DOI: 10.1007/s12032-012-0346-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
131 Akaza H, Oya M, Iijima M, Hyodo I, Gemma A, Itoh H, Adachi M, Okayama Y, Sunaya T, Inuyama L. A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance. Jpn J Clin Oncol 2015;45:953-62. [PMID: 26206897 DOI: 10.1093/jjco/hyv099] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
132 Hwang E, Lee HJ, Sul CK, Lim JS. Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience. Korean J Urol 2010;51:450-5. [PMID: 20664776 DOI: 10.4111/kju.2010.51.7.450] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
133 Vig SVL, Zan E, Kang SK. Imaging for Metastatic Renal Cell Carcinoma. Urol Clin North Am 2020;47:281-91. [PMID: 32600531 DOI: 10.1016/j.ucl.2020.04.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grisanzio C, Signoretti S. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol 2010;134:873-9. [PMID: 21088149 DOI: 10.1309/AJCPPPR57HNJMSLZ] [Cited by in Crossref: 66] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
135 Park HJ, Kim HJ, Park SH, Lee JS, Kim AY, Ha HK. Gastrointestinal Involvement of Recurrent Renal Cell Carcinoma: CT Findings and Clinicopathologic Features. Korean J Radiol 2017;18:452-60. [PMID: 28458597 DOI: 10.3348/kjr.2017.18.3.452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
136 Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, Hammers H, Hutson TE, Lee JL, Peltola K, Roth BJ, Bjarnason GA, Géczi L, Keam B, Maroto P, Heng DY, Schmidinger M, Kantoff PW, Borgman-Hagey A, Hessel C, Scheffold C, Schwab GM, Tannir NM, Motzer RJ; METEOR Investigators. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 2015;373:1814-23. [PMID: 26406150 DOI: 10.1056/NEJMoa1510016] [Cited by in Crossref: 666] [Cited by in F6Publishing: 310] [Article Influence: 95.1] [Reference Citation Analysis]
137 Yang W, Yoshigoe K, Qin X, Liu JS, Yang JY, Niemierko A, Deng Y, Liu Y, Dunker A, Chen Z, Wang L, Xu D, Arabnia HR, Tong W, Yang M. Identification of genes and pathways involved in kidney renal clear cell carcinoma. BMC Bioinformatics 2014;15 Suppl 17:S2. [PMID: 25559354 DOI: 10.1186/1471-2105-15-S17-S2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
138 He H, Zhuo R, Dai J, Wang X, Huang X, Wang H, Xu D. Chelerythrine induces apoptosis via ROS-mediated endoplasmic reticulum stress and STAT3 pathways in human renal cell carcinoma. J Cell Mol Med 2020;24:50-60. [PMID: 31568643 DOI: 10.1111/jcmm.14295] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
139 Wang Y, Zhang R, Wu D, Lu Z, Sun W, Cai Y, Wang C, Jin J. Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. J Exp Clin Cancer Res. 2013;32:8. [PMID: 23394073 DOI: 10.1186/1756-9966-32-8] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 4.2] [Reference Citation Analysis]
140 Kara O, Maurice MJ, Zargar H, Malkoc E, Akca O, Andrade HS, Ramirez D, Caputo PA, Nelson RJ, Rini B, Kaouk JH. Prognostic implications of sarcomatoid and rhabdoid differentiation in patients with grade 4 renal cell carcinoma. Int Urol Nephrol 2016;48:1253-60. [PMID: 27215555 DOI: 10.1007/s11255-016-1314-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
141 Diaz de Leon A, Pirasteh A, Costa DN, Kapur P, Hammers H, Brugarolas J, Pedrosa I. Current Challenges in Diagnosis and Assessment of the Response of Locally Advanced and Metastatic Renal Cell Carcinoma. Radiographics 2019;39:998-1016. [PMID: 31199711 DOI: 10.1148/rg.2019180178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
142 Chen P, Quan J, Jin L, Lin C, Xu W, Xu J, Guan X, Chen Z, Ni L, Yang S, Chen Y, Lai Y. miR-216a-5p acts as an oncogene in renal cell carcinoma. Exp Ther Med 2018;15:4039-46. [PMID: 29556270 DOI: 10.3892/etm.2018.5881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
143 Kim TW, Lee JH, Shim KH, Choo SH, Choi JB, Ahn HS, Kim SJ, Kim SI. Prognostic significance of preoperative and follow-up neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with non-metastatic clear cell renal cell carcinoma. Investig Clin Urol 2019;60:14-20. [PMID: 30637356 DOI: 10.4111/icu.2019.60.1.14] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
144 Rappold PM, Silagy AW, Kotecha RR, Hakimi AA. Immune checkpoint blockade in renal cell carcinoma. J Surg Oncol 2021;123:739-50. [PMID: 33595892 DOI: 10.1002/jso.26339] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
145 Yamasaki T, Seki N, Yamada Y, Yoshino H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Nakagawa M, Enokida H. Tumor suppressive microRNA138 contributes to cell migration and invasion through its targeting of vimentin in renal cell carcinoma. Int J Oncol. 2012;41:805-817. [PMID: 22766839 DOI: 10.3892/ijo.2012.1543] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
146 Kitajima K, Fukushima K, Yamamoto S, Kato T, Odawara S, Takaki H, Kobayashi K, Yamano T, Yamakado K, Nakanishi Y, Kanematsu A, Nojima M, Suzumura K, Hatano E, Fujimoto J, Kihara T, Nakasho K, Hirota S, Hirota S. 11C-Choline positive but 18F-FDG negative pancreatic metastasis from renal cell carcinoma on PET. Nagoya J Med Sci 2017;79:273-7. [PMID: 28626263 DOI: 10.18999/nagjms.79.2.273] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
147 Wang QS, Li F, Liao ZQ, Li K, Yang XL, Lin YY, Zhao YL, Weng SY, Xia Y, Ye Y, Li SH, Wang CY, Lin Y. Low level of Cyclin-D1 correlates with worse prognosis of clear cell renal cell carcinoma patients. Cancer Med 2019;8:4100-9. [PMID: 31183974 DOI: 10.1002/cam4.2313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
148 Zhang X, Yin X, Zhang H, Sun G, Yang Y, Chen J, Zhu X, Zhao P, Zhao J, Liu J, Chen N, Wang J, Shen P, Zeng H. Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. BMC Cancer 2019;19:360. [PMID: 30992011 DOI: 10.1186/s12885-019-5578-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
149 Xin J, Xu R, Lin S, Xin M, Cai W, Zhou J, Fu C, Zhen G, Lai J, Li Y, Zhang P. Clinical potential of TCF21 methylation in the diagnosis of renal cell carcinoma. Oncol Lett 2016;12:1265-70. [PMID: 27446425 DOI: 10.3892/ol.2016.4748] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
150 Di Furia M, Della Penna A, Salvatorelli A, Clementi M, Guadagni S. A single thyroid nodule revealing early metastases from clear cell renal carcinoma: case report and review of literature. Int J Surg Case Rep 2017;34:96-9. [PMID: 28376423 DOI: 10.1016/j.ijscr.2017.03.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
151 Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol 2018;74:611-20. [PMID: 29784193 DOI: 10.1016/j.eururo.2018.05.002] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
152 Cui L, Zhou H, Zhao H, Zhou Y, Xu R, Xu X, Zheng L, Xue Z, Xia W, Zhang B, Ding T, Cao Y, Tian Z, Shi Q, He X. MicroRNA-99a induces G1-phase cell cycle arrest and suppresses tumorigenicity in renal cell carcinoma. BMC Cancer 2012;12:546. [PMID: 23173671 DOI: 10.1186/1471-2407-12-546] [Cited by in Crossref: 67] [Cited by in F6Publishing: 72] [Article Influence: 6.7] [Reference Citation Analysis]
153 Méndez-Vidal MJ, Molina Á, Anido U, Chirivella I, Etxaniz O, Fernández-Parra E, Guix M, Hernández C, Lambea J, Montesa Á, Pinto Á, Ros S, Gallardo E. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma. BMC Pharmacol Toxicol 2018;19:77. [PMID: 30477570 DOI: 10.1186/s40360-018-0264-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
154 Mollica V, Brocchi S, Dall'Olio FG, Marcolin L, Paccapelo A, Santoni M, Rizzo A, Montironi R, Golfieri R, Massari F, Ardizzoni A. Tumor Growth Rate Decline despite Progressive Disease May Predict Improved Nivolumab Treatment Outcome in mRCC: When RECIST Is Not Enough. Cancers (Basel) 2021;13:3492. [PMID: 34298702 DOI: 10.3390/cancers13143492] [Reference Citation Analysis]
155 Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018;29:2371-8. [PMID: 30346481 DOI: 10.1093/annonc/mdy454] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 27.3] [Reference Citation Analysis]
156 Bayrak O, Sen H, Bulut E, Cengiz B, Karakok M, Erturhan S, Seckiner I. Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma. J Kidney Cancer VHL 2014;1:40-5. [PMID: 28326248 DOI: 10.15586/jkcvhl.2014.10] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
157 Xie W, Liu X, Chen Q, Ma M, Yang X, Gong B, Sun T, Chen J. Silencing of the long non-coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial-mesenchymal transition. Oncol Lett 2019;17:3173-80. [PMID: 30867747 DOI: 10.3892/ol.2019.9967] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
158 Buchner A, Castro M, Hennig A, Popp T, Assmann G, Hofstetter A, Stief C, Zimmermann W. [Transcriptome analyses in renal cell carcinoma. Combination of laser microdissection and microarrays]. Urologe A 2007;46:1170-5. [PMID: 17646957 DOI: 10.1007/s00120-007-1473-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
159 Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 2005;6:7-18. [PMID: 15610692 DOI: 10.1007/s11934-005-0062-x] [Cited by in Crossref: 77] [Cited by in F6Publishing: 64] [Article Influence: 4.5] [Reference Citation Analysis]
160 Crispen PL, Boorjian SA, Lohse CM, Leibovich BC, Kwon ED. Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers. Cancer 2008;113:450-60. [PMID: 18523999 DOI: 10.1002/cncr.23566] [Cited by in Crossref: 66] [Cited by in F6Publishing: 53] [Article Influence: 4.7] [Reference Citation Analysis]
161 Di JH, Qu DB, Lu Z, Li LT, Cheng Q, Xin Y, Zhang LZ, Zhang Y, Zheng JN. Rap2B promotes migration and invasion of human suprarenal epithelioma. Tumour Biol 2014;35:9387-94. [PMID: 24951956 DOI: 10.1007/s13277-014-2174-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
162 Peisen F, Thaiss W, Tietze N, Rausch S, Amend B, Nikolaou K, Bedke J, Stenzl A, Kaufmann S. [Influence of immunomodulators on urological imaging]. Urologe A 2019;58:1451-60. [PMID: 31705144 DOI: 10.1007/s00120-019-01063-1] [Reference Citation Analysis]
163 Haddad AQ, Margulis V. Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol 2015;12:253-62. [PMID: 25868564 DOI: 10.1038/nrurol.2015.71] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
164 Tai CG, Johnson TV, Abbasi A, Herrell L, Harris WB, Kucuk O, Canter DJ, Ogan K, Pattaras JG, Nieh PT, Master VA. External validation of the modified Glasgow prognostic score for renal cancer. Indian J Urol 2014;30:33-7. [PMID: 24497679 DOI: 10.4103/0970-1591.124203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
165 Aslam S, Eisen T. Vascular endothelial growth factor receptor tyrosine kinase inhibitors in metastatic renal cell cancer: latest results and clinical implications. Ther Adv Med Oncol 2013;5:324-33. [PMID: 24179487 DOI: 10.1177/1758834013507966] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
166 Zhang X, Yin X, Zhang H, Sun G, Yang Y, Chen J, Shu K, Zhao J, Zhao P, Chen N, Wang J, Shen P, Zeng H. Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. BMC Cancer 2019;19:49. [PMID: 30630458 DOI: 10.1186/s12885-019-5273-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
167 Kunkle DA, Haas NB, Uzzo RG. Adjuvant therapy for high-risk renal cell carcinoma patients. Curr Urol Rep 2007;8:19-30. [PMID: 17239313 DOI: 10.1007/s11934-007-0017-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
168 Li XQ, Pei DS, Qian GW, Yin XX, Cheng Q, Li LT, Li HZ, Zheng JN. The effect of methylated oligonucleotide targeting Ki-67 gene in human 786-0 renal carcinoma cells. Tumour Biol 2011;32:863-72. [PMID: 21598043 DOI: 10.1007/s13277-011-0187-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
169 Diaz de Leon A, Pedrosa I. Imaging and Screening of Kidney Cancer. Radiol Clin North Am. 2017;55:1235-1250. [PMID: 28991563 DOI: 10.1016/j.rcl.2017.06.007] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
170 Wen JL, Wen XF, Li RB, Jin YC, Wang XL, Zhou L, Chen HX. UBE3C promotes growth and metastasis of renal cell carcinoma via activating Wnt/β-catenin pathway. PLoS One 2015;10:e0115622. [PMID: 25658088 DOI: 10.1371/journal.pone.0115622] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
171 Lkhagvadorj S, Oh SS, Lee MR, Jung JH, Chung HC, Cha SK, Eom M. Insulin receptor expression in clear cell renal cell carcinoma and its relation to prognosis. Yonsei Med J 2014;55:861-70. [PMID: 24954312 DOI: 10.3349/ymj.2014.55.4.861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
172 Keizman D, Ish-Shalom M, Maimon N, Gottfried M. Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases? World J Urol 2014;32:39-45. [PMID: 23543006 DOI: 10.1007/s00345-013-1059-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
173 Zianne M, Takahashi N, Tsujibata A, Miwa K, Goto Y, Matano Y. Asymptomatic Pancreatic Metastasis from Renal Cell Carcinoma Diagnosed 21 Years after Nephrectomy. Case Rep Gastrointest Med 2017;2017:8765264. [PMID: 28951792 DOI: 10.1155/2017/8765264] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
174 Wang Y, Chen SX, Rao X, Liu Y. Modulator-Dependent RBPs Changes Alternative Splicing Outcomes in Kidney Cancer. Front Genet 2020;11:265. [PMID: 32273884 DOI: 10.3389/fgene.2020.00265] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
175 Ebert T, Fischer C. [When is aftercare useful in renal cell cancer?]. Urologe A 2005;44:1018, 1020-3. [PMID: 16047197 DOI: 10.1007/s00120-005-0880-y] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
176 Barth DA, Drula R, Ott L, Fabris L, Slaby O, Calin GA, Pichler M. Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers. Front Cell Dev Biol 2020;8:828. [PMID: 33042985 DOI: 10.3389/fcell.2020.00828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
177 Liu Z, Lu Y, He Z, Chen L, Lu Y. Expression analysis of the estrogen receptor target genes in renal cell carcinoma. Mol Med Rep 2015;11:75-82. [PMID: 25351113 DOI: 10.3892/mmr.2014.2766] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
178 Tsuruda M, Yoshino H, Okamura S, Kuroshima K, Osako Y, Sakaguchi T, Sugita S, Tatarano S, Nakagawa M, Enokida H. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. PLoS One 2020;15:e0232545. [PMID: 32379831 DOI: 10.1371/journal.pone.0232545] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
179 Chao X, Wang P, Ma X, Li Z, Xia Y, Guo Y, Ge L, Tian L, Zheng H, Du Y, Li J, Zuo Z, Xie L, Guo X. Comprehensive analysis of lncRNAs as biomarkers for diagnosis, prognosis, and treatment response in clear cell renal cell carcinoma. Mol Ther Oncolytics 2021;22:209-18. [PMID: 34514100 DOI: 10.1016/j.omto.2021.08.003] [Reference Citation Analysis]
180 Zołnierek J, Nurzyński P, Langiewicz P, Oborska S, Waśko-Grabowska A, Kuszatal E, Obrocka B, Szczylik C. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 2010;136:371-8. [PMID: 19711099 DOI: 10.1007/s00432-009-0664-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
181 Minardi D, Lucarini G, Filosa A, Milanese G, Zizzi A, Primio RD, Montironi R, Muzzonigro G. Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med 2009;13:2115-21. [PMID: 18752633 DOI: 10.1111/j.1582-4934.2008.00482.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
182 Gu Y, Lu L, Wu L, Chen H, Zhu W, He Y. Identification of prognostic genes in kidney renal clear cell carcinoma by RNA‑seq data analysis. Mol Med Rep 2017;15:1661-7. [PMID: 28260099 DOI: 10.3892/mmr.2017.6194] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
183 Kim H, Komiyama T, Inomoto C, Kamiguchi H, Kajiwara H, Kobayashi H, Nakamura N, Terachi T. Mutations in the Mitochondrial ND1 Gene Are Associated with Postoperative Prognosis of Localized Renal Cell Carcinoma. Int J Mol Sci 2016;17:E2049. [PMID: 27941608 DOI: 10.3390/ijms17122049] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
184 Chen XM, Zhang M, Fan PL, Qin YH, Zhao HW. Chelerythrine chloride induces apoptosis in renal cancer HEK-293 and SW-839 cell lines. Oncol Lett 2016;11:3917-24. [PMID: 27313717 DOI: 10.3892/ol.2016.4520] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
185 Liu J, Liu J, Wang S, Zhao H, Tian C, Shi B, Jiang X. Three-dimensional nephrometry scoring system: a precise scoring system to evaluate complexity of renal tumors suitable for partial nephrectomy. PeerJ 2020;8:e8637. [PMID: 32149027 DOI: 10.7717/peerj.8637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Kim BJ, Kim JH, Kim HS, Zang DY. Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. Oncotarget 2017;8:13979-85. [PMID: 28103578 DOI: 10.18632/oncotarget.14704] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
187 Abdelaziz LA, Taha HF, Ali MM, Abdelgawad MI, Elwan A. Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study. Contemp Oncol (Pozn) 2020;24:221-8. [PMID: 33531869 DOI: 10.5114/wo.2020.102802] [Reference Citation Analysis]
188 Lee BH, Feifer A, Feuerstein MA, Benfante NE, Kou L, Yu C, Kattan MW, Russo P. Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma. Eur Urol Focus 2018;4:100-5. [PMID: 28753780 DOI: 10.1016/j.euf.2016.07.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
189 Li M, Wang Y, Song Y, Bu R, Yin B, Fei X, Guo Q, Wu B. MicroRNAs in renal cell carcinoma: a systematic review of clinical implications (Review). Oncol Rep 2015;33:1571-8. [PMID: 25682771 DOI: 10.3892/or.2015.3799] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
190 Small J, Washburn E, Millington K, Zhu J, Holder SL. The addition of abemaciclib to sunitinib induces regression of renal cell carcinoma xenograft tumors. Oncotarget 2017;8:95116-34. [PMID: 29221116 DOI: 10.18632/oncotarget.19618] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
191 Maybody M. An overview of image-guided percutaneous ablation of renal tumors. Semin Intervent Radiol 2010;27:261-7. [PMID: 22550365 DOI: 10.1055/s-0030-1261784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
192 Jiang L, Liu Y, Ma C, Li B. MicroRNA-30a suppresses the proliferation, migration and invasion of human renal cell carcinoma cells by directly targeting ADAM9. Oncol Lett 2018;16:3038-44. [PMID: 30127894 DOI: 10.3892/ol.2018.8999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
193 Sridhar SS, Mackenzie MJ, Hotte SJ, Mukherjee SD, Tannock IF, Murray N, Kollmannsberger C, Haider MA, Chen EX, Halford R, Wang L, Ivy SP, Moore MJ. A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium. Invest New Drugs 2013;31:1008-15. [PMID: 23354849 DOI: 10.1007/s10637-013-9931-1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
194 Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Murakami T, Kishida T, Miura T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Inoue T, Kubota Y, Nakaigawa N. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 2012;12:162. [PMID: 22551397 DOI: 10.1186/1471-2407-12-162] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.9] [Reference Citation Analysis]
195 Maia MC, Salgia M, Pal SK. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat Rev Urol 2020;17:271-91. [PMID: 32203306 DOI: 10.1038/s41585-020-0297-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
196 Gajendra S, Sachdev R, Mohapatra I, Goel R, Goel S. Metastatic Renal Cell Carcinoma: An Unusual Cause of Bleeding Pancreatic Mass. J Clin Diagn Res. 2015;9:ED15-ED17. [PMID: 26500917 DOI: 10.7860/jcdr/2015/14350.6519] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
197 Kang M, Shin SJ, Sung HH, Jeon HG, Jeong BC, Jeon SS, Lee HM, Seo SI. Clinical Significance of Pre-to-Postoperative Dynamics of Aspartate Transaminase/Alanine Transaminase Ratio in Predicting the Prognosis of Renal Cell Carcinoma after Surgical Treatment. Dis Markers 2020;2020:8887605. [PMID: 32724485 DOI: 10.1155/2020/8887605] [Reference Citation Analysis]
198 Carril-Ajuria L, Santos M, Roldán-Romero JM, Rodriguez-Antona C, de Velasco G. Prognostic and Predictive Value of PBRM1 in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2019;12:E16. [PMID: 31861590 DOI: 10.3390/cancers12010016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
199 Dragomir A, Aprikian A, Kapoor A, Finelli A, Pouliot F, Rendon R, Black PC, Moore R, Breau RH, Kawakami J, Drachenberg D, Lattouf JB, Tanguay S. Follow-up imaging after nephrectomy for cancer in Canada: urologists' compliance with guidelines. An observational study. CMAJ Open 2017;5:E834-41. [PMID: 29229610 DOI: 10.9778/cmajo.20170005] [Reference Citation Analysis]
200 Mejean A, Correas JM, Escudier B, de Fromont M, Lang H, Long JA, Neuzillet Y, Patard JJ, Piechaud T. [Kidney tumors]. Prog Urol 2007;17:1101-44. [PMID: 18153989 DOI: 10.1016/s1166-7087(07)74782-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
201 Butz H, Ding Q, Nofech-Mozes R, Lichner Z, Ni H, Yousef GM. Elucidating mechanisms of sunitinib resistance in renal cancer: an integrated pathological-molecular analysis. Oncotarget 2018;9:4661-74. [PMID: 29435133 DOI: 10.18632/oncotarget.23163] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
202 Ma H, Tan Y, Wen D, Qu N, Kong Q, Li K, Ma S, Zhang J. DC-CTL targeting carbonic anhydrase IX gene combined with iAPA therapy in the treatment of renal cell carcinoma. Hum Vaccin Immunother 2021;:1-11. [PMID: 34851805 DOI: 10.1080/21645515.2021.1955610] [Reference Citation Analysis]
203 Cho D, McDermott D, Atkins M. Designing clinical trials for kidney cancer based on newly developed prognostic and predictive tools. Curr Urol Rep 2006;7:8-15. [PMID: 16480663 DOI: 10.1007/s11934-006-0032-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
204 Keizman D, Ish-Shalom M, Huang P, Eisenberger MA, Pili R, Hammers H, Carducci MA. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012;48:202-8. [PMID: 22018713 DOI: 10.1016/j.ejca.2011.09.001] [Cited by in Crossref: 129] [Cited by in F6Publishing: 130] [Article Influence: 11.7] [Reference Citation Analysis]
205 Chen SJ, Yao XD, Peng BO, Xu YF, Wang GC, Huang J, Liu M, Zheng JH. Epigallocatechin-3-gallate inhibits migration and invasion of human renal carcinoma cells by downregulating matrix metalloproteinase-2 and matrix metalloproteinase-9. Exp Ther Med 2016;11:1243-8. [PMID: 27073430 DOI: 10.3892/etm.2016.3050] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
206 Wood CG, Ferguson JE 3rd, Parker JS, Moore DT, Whisenant JG, Maygarden SJ, Wallen EM, Kim WY, Milowsky MI, Beckermann KE, Davis NB, Haake SM, Karam JA, Bortone DS, Vincent BG, Powles T, Rathmell WK. Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. JCI Insight 2020;5:132852. [PMID: 33208553 DOI: 10.1172/jci.insight.132852] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
207 Motzer RJ, Hudes G, Wilding G, Schwartz LH, Hariharan S, Kempin S, Fayyad R, Figlin RA. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009;7:28-33. [PMID: 19213665 DOI: 10.3816/CGC.2009.n.005] [Cited by in Crossref: 54] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
208 Zhang X, Yan L, Jiao W, Ren J, Xing N, Zhang Y, Zang Y, Wang J, Xu Z. The clinical and biological significance of MICA in clear cell renal cell carcinoma patients. Tumour Biol 2016;37:2153-9. [PMID: 26349747 DOI: 10.1007/s13277-015-4041-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
209 Li Y, Li J, Sun X, Chen J, Sun X, Zheng J, Chen R. MicroRNA-27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor. Oncol Lett 2016;11:4217-23. [PMID: 27313769 DOI: 10.3892/ol.2016.4500] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]